• In the second quarter of 2026, Mirum Pharmaceuticals reported a net loss of US$67.23 million, or US$1.06 per share, and for the first half of 2026 its net loss widened to a very large US$857.38 million, or US$14.03 per share, even as it raised full-year 2026 product sales guidance to US$680 million–US$700 million on stronger-than-expected revenue including US$176 million in second-quarter sales.
• An important nuance for investors is that while LIVMARLI’s US$129 million in quarterly sales and higher cash contribution margins underscored robust commercial traction, the FDA’s request for another Phase III study delayed a planned U.S. filing for volixibat in PSC pruritus to the first half of 2027, adding uncertainty around Mirum’s longer-term pipeline outlook.
• We’ll now explore how stronger current product sales, set against the FDA-driven delay for volixibat, reshape Mirum Pharmaceuticals’ broader investment narrative.

The latest GPUs need a type of rare earth metal called Terbium and there are only 28 companies in the world exploring or producing it. Find the list for free.

Mirum Pharmaceuticals Investment Narrative Recap

To own Mirum Pharmaceuticals, you need to believe LIVMARLI can keep supporting growing product sales while the broader pipeline eventually adds new revenue streams. The latest results reinforce that near term, the key catalyst is continued LIVMARLI uptake and margin improvement, while the biggest risk is now the FDA driven delay for volixibat, which pushes out one potential diversification pillar but does not immediately alter the commercial story already in place.

The most relevant recent announcement here is Mirum’s decision to raise full year 2026 net product sales guidance to US$680 million to US$700 million after reporting US$176 million in second quarter sales. That update sits in sharp contrast to the sharply wider net loss of US$857.38 million in the first half, and it frames the core tension in the story: stronger current cash contribution from LIVMARLI on one side, and heavier investment and regulatory uncertainty around volixibat and the rest of the pipeline on the other.

Yet despite stronger guidance, investors should be aware that concentrated reliance on LIVMARLI and heightened regulatory demands for volixibat could still...

Mirum Pharmaceuticals' narrative projects $1.1 billion revenue and $234.1 million earnings by 2029.

Uncover how Mirum Pharmaceuticals' forecasts yield a $144.15 fair value, a 43% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already assuming Mirum would need about US$1.0 billion in revenue and only US$81.7 million in earnings by 2029, so if you are worried about tougher drug pricing and higher regulatory hurdles after this FDA setback, you might see their more pessimistic narrative as increasingly relevant, while others may still view the raised 2026 sales guidance as a sign that these cautious views could be revised over time.

Explore 3 other fair value estimates on Mirum Pharmaceuticals - why the stock might be worth just $118.11!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Mirum Pharmaceuticals research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Mirum Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mirum Pharmaceuticals' overall financial health at a glance.

Contemplating Other Strategies?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 51 companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.